Advancing Anticoagulant Therapies with Ethyl 3-(pyridin-2-ylamino)propanoate
The field of anticoagulant therapy has seen significant advancements, with direct thrombin inhibitors playing a crucial role in preventing and treating thrombotic events. At the heart of producing these life-saving medications is the availability of critical pharmaceutical intermediates like Ethyl 3-(pyridin-2-ylamino)propanoate (CAS 103041-38-9). This white powder compound, with its molecular formula C10H14N2O2 and molecular weight of 194.23, serves as a vital building block for synthesizing compounds such as Dabigatran Etexilate. NINGBO INNO PHARMCHEM CO.,LTD., a prominent pharmaceutical intermediate manufacturer in China, is dedicated to supplying this essential chemical to support the global healthcare sector.
Ethyl 3-(pyridin-2-ylamino)propanoate's primary utility lies in its incorporation into the molecular structure of potent thrombin inhibitors. Thrombin, a key enzyme in the coagulation cascade, is a prime target for anticoagulants aimed at reducing the risk of blood clots, stroke, and other serious conditions. The precise chemical structure and high purity of this intermediate, ensured by manufacturers like NINGBO INNO PHARMCHEM CO.,LTD., are indispensable for the efficacy and safety of the final drug product.
The demand for effective anticoagulants is projected to continue its upward trajectory, driven by an aging global population and the increasing incidence of conditions like atrial fibrillation and deep vein thrombosis. This sustained demand translates into a consistent need for high-quality Ethyl 3-(pyridin-2-ylamino)propanoate. Pharmaceutical companies looking to buy this intermediate can rely on NINGBO INNO PHARMCHEM CO.,LTD. for a dependable supply, sourced from advanced manufacturing facilities in China. The company's commitment to quality control, including precise storage conditions (dark, inert atmosphere, 2-8°C) and careful handling, guarantees the intermediate's integrity.
The efficient synthesis of Ethyl 3-(pyridin-2-ylamino)propanoate, utilizing common raw materials like 2-aminopyridine and ethyl acrylate, is a key factor in its accessibility. NINGBO INNO PHARMCHEM CO.,LTD. leverages optimized chemical processes to ensure cost-effectiveness without compromising on purity. This makes it an attractive option for pharmaceutical companies seeking to manage their production costs while maintaining high standards for their API intermediates. Whether for R&D purposes or large-scale commercial production, the ability to purchase this compound reliably is a significant advantage.
For pharmaceutical manufacturers, securing a stable supply chain for critical intermediates is a strategic imperative. NINGBO INNO PHARMCHEM CO.,LTD. provides a robust solution for sourcing Ethyl 3-(pyridin-2-ylamino)propanoate. Their expertise as a manufacturer and supplier in China, combined with their dedication to customer service and regulatory compliance, makes them an ideal partner. By choosing NINGBO INNO PHARMCHEM CO.,LTD., companies can ensure the continuity of their drug development and manufacturing processes, ultimately contributing to better patient outcomes in anticoagulant therapy.
In conclusion, Ethyl 3-(pyridin-2-ylamino)propanoate is a cornerstone in the synthesis of advanced anticoagulant therapies. Its role in producing thrombin inhibitors directly impacts the availability of critical medications. NINGBO INNO PHARMCHEM CO.,LTD. stands as a key enabler in this process, providing a reliable source of this vital pharmaceutical intermediate. For manufacturers seeking to enhance their anticoagulant drug production, exploring options to buy Ethyl 3-(pyridin-2-ylamino)propanoate from NINGBO INNO PHARMCHEM CO.,LTD. is a strategic step towards achieving their goals.
Perspectives & Insights
Future Origin 2025
“For pharmaceutical manufacturers, securing a stable supply chain for critical intermediates is a strategic imperative.”
Core Analyst 01
“Their expertise as a manufacturer and supplier in China, combined with their dedication to customer service and regulatory compliance, makes them an ideal partner.”
Silicon Seeker One
“, companies can ensure the continuity of their drug development and manufacturing processes, ultimately contributing to better patient outcomes in anticoagulant therapy.”